Pharmacovigilance
PSMF essentials: 7 things often missed in a first inspection.
A practical list of areas teams should review before auditors ask for the full PV system story.
May 20266 min read
Knowledge Hub
Launch-ready topics for high-intent readers.
Regulatory Affairs
Choosing the right EU regulatory pathway: CP vs MRP vs DCP.
How to frame the pathway decision based on product type, target countries, evidence, and timeline.
May 20267 min read
Pharmacovigilance
Signal management under GVP Module IX: a practical workflow.
A clear operating model for detection, validation, prioritization, evaluation, and QPPV review.
May 20268 min read
Materiovigilance
What device manufacturers should set up before MDR scrutiny.
Post-market surveillance, vigilance reporting, FSCA/FSN coordination, and documentation readiness.
May 20265 min read
Regulatory Affairs
Virtual MAH and fractional QPPV: when they make sense.
A decision guide for companies entering the UK or EU without a fully built local operating model.
May 20266 min read
Industry News
How to turn regulatory intelligence into monthly operating action.
A lightweight approach to monitoring change, assigning ownership, and proving action during audits.
May 20264 min read
Home / Insights / PSMF essentials
PSMF essentials: 7 things often missed in a first inspection.
PharmaRevix EditorialMay 20266 min read
A Pharmacovigilance System Master File should give inspectors a current, accurate view of how your safety system is governed, resourced, measured, and improved.
Inspection readiness is not only documentation. It is evidence that the PV system is operating the way the file says it operates.
Common gaps include stale vendor oversight records, mismatched safety database descriptions, missing local literature responsibilities, outdated QPPV contact details, incomplete CAPA linkage, and SOP references that no longer match active practice.
PharmaRevix helps companies refresh PSMF content, align SOPs, prepare evidence packs, and define practical governance routines before an inspection timeline becomes urgent.
Need help applying this in your organization?
Book a free call with PharmaRevix to translate regulatory or PV guidance into a practical plan.
Book a Free Consultation